A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3 ...
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
The US Food and Drug Administration announced this month that it's effectively banning Red No. 3, the controversial ...
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...
Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.